In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds
Gespeichert in:
| Titel: | In vitro susceptibility of 10 clinical isolates of SARS coronavirus to selected antiviral compounds |
|---|---|
| Autoren: | Fan, KW, Yuen, KY, Kao, RYT, Cheng, VCC, Hung, IFN, Peiris, JSM, Lu, HT, Jiang, Y, Guan, Y, Lee, TSW, Tsui, WHW, Chen, SF, Chan, KH |
| Quelle: | J Clin Virol |
| Verlagsinformationen: | Elsevier BV, 2004. |
| Publikationsjahr: | 2004 |
| Schlagwörter: | Adult, Male, 0301 basic medicine, Sars Virus - Drug Effects, Short Communication, Glycyrrhizic Acid - Chemistry - Pharmacology, Pyrimidinones - Pharmacology, Flavonoids - Chemistry - Pharmacology, Viral Plaque Assay, Microbial Sensitivity Tests, Pyrimidinones, Antiviral Agents, Lopinavir, Cell Line, 03 medical and health sciences, Rimantadine, Ribavirin, Humans, Epidemics, Ribavirin - Pharmacology, Flavonoids, 0303 health sciences, Severe Acute Respiratory Syndrome - Virology, Antiviral Agents - Pharmacology, Rimantadine - Pharmacology, Interferon-alpha, Drug Synergism, Interferon-beta, Middle Aged, Interferon-Alpha - Pharmacology, Glycyrrhizic Acid, 3. Good health, Severe acute respiratory syndrome, Interferon-Beta - Pharmacology, Severe acute respiratory syndrome-related coronavirus, Female, Antiviral compounds, Chlorogenic Acid, Chlorogenic Acid - Chemistry - Pharmacology, Interferon beta-1a |
| Beschreibung: | Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-1a, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics. |
| Publikationsart: | Article Other literature type |
| Sprache: | English |
| ISSN: | 1386-6532 |
| DOI: | 10.1016/j.jcv.2004.03.003 |
| Zugangs-URL: | https://pubmed.ncbi.nlm.nih.gov/15288617 https://pubmed.ncbi.nlm.nih.gov/15288617/ http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128415 http://hub.hku.hk/handle/10722/163121 http://www.sciencedirect.com/science/article/pii/S1386653204000551 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7128415 https://covid19.elsevierpure.com/pl/publications/in-vitro-susceptibility-of-10-clinical-isolates-of-sars-coronavir http://hdl.handle.net/10722/163121 |
| Rights: | Elsevier TDM |
| Dokumentencode: | edsair.doi.dedup.....dd5e58569e97b7b87ce1c5e5e29d6867 |
| Datenbank: | OpenAIRE |
Full Text Finder 
Nájsť tento článok vo Web of Science | Abstract: | Effective antiviral agents are urgently needed to combat the possible return of severe acute respiratory syndrome (SARS). Commercial antiviral agents and pure chemical compounds extracted from traditional Chinese medicinal herbs were screened against 10 clinical isolates of SARS coronavirus by neutralisation tests with confirmation by plaque reduction assays. Interferon-beta-1a, leukocytic interferon-alpha, ribavirin, lopinavir, rimantadine, baicalin and glycyrrhizin showed antiviral activity. The two interferons were only active if the cell lines were pre-incubated with the drugs 16 h before viral inoculation. Results were confirmed by plaque reduction assays. Antiviral activity varied with the use of different cell lines. Checkerboard assays for synergy were performed showing combinations of interferon beta-1a or leukocytic interferon-alpha with ribavirin are synergistic. Since the clinical and toxicity profiles of these agents are well known, they should be considered either singly or in combination for prophylaxis or treatment of SARS in randomised placebo controlled trials in future epidemics. |
|---|---|
| ISSN: | 13866532 |
| DOI: | 10.1016/j.jcv.2004.03.003 |